검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Trimethoprim-sulfamethoxazole (Trimethoprim-sulfamethoxazole) Pfizer·Chronic Myeloproliferative Disorde… ORR 0.00% |
|---|---|
Overview Program | Trimethoprim-sulfamethoxazole |
Overview Company | Pfizer |
Overview Modality | CGT |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Infection |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted immunomodulators, including chimeric antigen receptor |
PK/PD Species | Beagle dog, Dog |
PK/PD Animal (cat.) | Dog |
PK/PD Experiment | pd |
Toxicology Species | Beagle dog, Dog |
Toxicology Animal (cat.) | Dog |
Toxicology Major finding | Emerging Antibiotics for Urinary Tract Infections: Clinical Implications for Women's Health.. To review recently Food and Drug Administration (FDA)-approved antibiotics (2017-2026) for complicated and resistant urinary tract infections (UTIs), focusing on their pharmacology, spectrum of activity, clinical evidence, and potential role in the management of UTIs specifically in women. Information was… |
Clinical ORR | 0.00% |
Clinical Result source | ClinicalTrials.gov NCT02164461 |
Clinical Data Tier / Score | A · 13 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Trimethoprim-sulfamethoxazole (Trimethoprim-sulfamethoxazole) Pfizer·Chronic Myeloproliferative Disorde… ORR 0.00% |
|---|---|
Overview Program | Trimethoprim-sulfamethoxazole |
Overview Company | Pfizer |
Overview Modality | CGT |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Infection |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted immunomodulators, including chimeric antigen receptor |
PK/PD Species | Beagle dog, Dog |
PK/PD Animal (cat.) | Dog |
PK/PD Experiment | pd |
Toxicology Species | Beagle dog, Dog |
Toxicology Animal (cat.) | Dog |
Toxicology Major finding | Emerging Antibiotics for Urinary Tract Infections: Clinical Implications for Women's Health.. To review recently Food and Drug Administration (FDA)-approved antibiotics (2017-2026) for complicated and resistant urinary tract infections (UTIs), focusing on their pharmacology, spectrum of activity, clinical evidence, and potential role in the management of UTIs specifically in women. Information was… |
Clinical ORR | 0.00% |
Clinical Result source | ClinicalTrials.gov NCT02164461 |
Clinical Data Tier / Score | A · 13 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교